Shots:
- VaxEquity can receive ~$195M in development, approval, and sales-based milestones along with royalties per program & is also eligible to receive an equity investment from AstraZeneca for the development of the saRNA platform
- The focus of the collaboration is to optimize and validate VaxEquity’s saRNA platform to advance novel therapeutic programs
- AstraZeneca support VaxEquity with R&D funding to advance any of the research programs into its pipeline & gets an option to collaborate with VaxEquity on up to 26 drug targets
Click here to read full press release/ article | Ref: AstraZeneca | Image: The Scientist Magazine
The post AstraZeneca Collaborates with VaxEquity to Develop and Commercialize Self-Amplifying RNA Therapeutics first appeared on PharmaShots.
